Cytokeratin 19 antibody
Quick Overview for Cytokeratin 19 antibody (ABIN5707735)
Target
See all Cytokeratin 19 (KRT19) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- Purified
-
Purity
- Protein A affinity chromatography
-
Immunogen
- Human mammary epithelial organoids were used as the immunogen for the recombinant KRT19 antibody.
-
Isotype
- IgG kappa
-
-
-
-
Application Notes
-
Optimal dilution of the recombinant KRT19 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1) -
Restrictions
- For Research Use only
-
-
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the recombinant KRT19 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- Cytokeratin 19 (KRT19) (Keratin 19 (KRT19))
-
Alternative Name
- KRT19 / Cytokeratin 19
-
Background
- Recognizes a protein of 40 kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50 % -60 % of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.
Target
-